SAGE Therapeutics Inc. (SAGE: NSD) has recently encountered unforeseen turbulence. A new risk has emerged and is adding pressure to the biotech firm’s stock value. Regulatory review delays over their depression drug, SAGE-217, have raised safety concerns, presenting a potential impact on SAGE Therapeutics’ stock price.
Stock Target Advisor’s Take on SAGE Therapeutics:
Stock Target Advisor advises a ‘Strong Sell’ rating on SAGE Therapeutics stock, presenting a firm target price of 23.33. With a projected price change expected to fall by -9.39% over the next 12 months, it’s clear to see why the stock raises concerns. The average analyst target price for Sage Therapeutic stands at USD 24.64, a shade higher, with a collective average rating of ‘Buy’.
The market offers a brighter perspective on SAGE Therapeutics, with seven covering analysts collectively advising a ‘Buy’ rating. The average price target stands at 24.64, with values ranging from a minimum target price of 18 to a maximum of 34.
SAGE Therapeutics operates under the biotechnology sector, which currently receives an average analyst rating of ‘Strong Buy.’ Conversely, Stock Target Advisor leans bearish on this sector.
SAGE Therapeutics: An Overview of Financial Performance
Over the past year, SAGE Therapeutics’ stock suffered a capital loss of -42.92%, ranking it on the 40.09th percentile on sectorial capital gains. No dividend returns were realized, generating a gross total return equal to the listed capital loss.
In terms of profitability ratios, SAGE Therapeutics exhibits a -33.77% Return on Assets (RoA), a -59.72% Return on Equity (RoE), and a -34.71% Return on Invested Capital (RoIC). Again, the percentile ranking within the sector for these ratios requires understanding.
Bottom Line:
Based on the insights, investors should carefully evaluate the new risk’s impact on SAGE Therapeutics’ stock value. Before investing decisions, extensive study and prudence are needed due to regulatory delays.
Muzzammil is a content writer at Stock Target Advisor. He has been writing stock news and analysis at Stock Target Advisor since 2023 and has worked in the financial domain in various roles since 2020. He has previously worked on an equity research firm that analyzed companies listed on the stock markets in the U.S. and Canada and performed fundamental and qualitative analyses of management strength, business strategy, and product/services forecast as indicated by major brokers covering the stock.
